Related Experiment Video
Updated: Dec 23, 2025
Fixation and Operational Method for Abdominal Massage in T2DM Mice
Published on: March 7, 2025
Metformin ameliorates animal models of dermatitis
Soo Young Choi1, Chanmi Lee1, Min-Jeong Heo1
1Korea Institute of Dermatological Science, GeneCellPharm Corporation, 375 Munjeong 2(i)-dong, Songpa-gu, Seoul, 05836, South Korea.
Abstract:
Metformin, a potent AMPK activator is the most commonly used drug for diabetes. According to recent reports, metformin lowers the risk of diabetic complications and inflammatory diseases. We found the expression levels of AMPK subunits including PRKAA1, PRKAA2, PRKAB1 and PRKAB2 are decreased in skin biopsies of dermatitis patients from multiple datasets. Interestingly, metformin treatment ameliorates dermatitis symptom in animal model of dermatitis using O-tetradecanoylphorbol-13-acetate (TPA). Especially, the levels of epidermis and dermis thickness were decreased by metformin. We found NFκB activity as well as of gene expression associated with collagen synthesis are attenuated by metformin treatment. These results suggest that metformin treatment alleviates animal model of dermatitis.
Insights
Metformin, an AMPK activator, reduces dermatitis symptoms in animal models. It decreases skin thickness and inhibits inflammation-related gene expression, suggesting therapeutic potential for inflammatory skin diseases.
Area of Science:
- Dermatology
- Pharmacology
- Molecular Biology
Background:
- Metformin is a widely used antidiabetic drug known to activate AMP-activated protein kinase (AMPK).
- Recent studies suggest metformin's potential in managing inflammatory diseases and diabetic complications.
- Reduced expression of AMPK subunits (PRKAA1, PRKAA2, PRKAB1, PRKAB2) has been observed in dermatitis patients.
Purpose of the Study:
- To investigate the therapeutic effect of metformin on an animal model of dermatitis.
- To explore the underlying molecular mechanisms of metformin's action in dermatitis.
Main Methods:
- Utilized an O-tetradecanoylphorbol-13-acetate (TPA)-induced animal model of dermatitis.
- Administered metformin to the animal model.
- Assessed changes in skin thickness (epidermis and dermis).
- Measured Nuclear Factor-kappa B (NFκB) activity and gene expression related to collagen synthesis.
Main Results:
- Metformin treatment significantly ameliorated dermatitis symptoms in the TPA-induced animal model.
- Metformin administration led to a reduction in both epidermal and dermal thickness.
- NFκB activity and the expression of collagen synthesis-associated genes were attenuated by metformin.
Conclusions:
- Metformin demonstrates a therapeutic effect in an animal model of dermatitis.
- The anti-inflammatory and skin-modulating effects of metformin may be mediated through the inhibition of NFκB signaling and collagen synthesis pathways.
- Metformin shows promise as a potential treatment for inflammatory skin conditions like dermatitis.
